SCHEMBL889358

SCHEMBL889358

CC(C)c1ccc2[nH]c(C(C)C)nc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.59
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
SCN10A Q9Y5Y9 2/20 0.53
MLKL Q8NB16 4/20 0.51
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.40
KIF11 P52732 1/20 0.40
EIF4A3 P38919 2/20 0.39
TAAR1 Q96RJ0 1/20 0.38
ALOX15 P16050 1/20 0.38
IDO1 P14902 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
SCN4A P35499 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18931187 0.88 HSD17B10 (0.54) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL798790 0.85 SCN10A (0.69) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL15172646 0.82 SCN10A (0.79) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL12032930 0.81 HSD17B10 (0.64) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL6888843 0.81 ALDH1A1 (0.44) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL2757079 0.81 KDM4E (0.59) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL15172655 0.80 SCN10A (0.57) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL15172696 0.80 SCN10A (0.63) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL15157108 0.80 SCN10A (0.57) HSD17B10KDM4ELMNASCN10AMLKL
SCHEMBL24076512 0.80 HSD17B10 (0.57) HSD17B10KDM4ELMNASCN10AMLKL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20230348422-A1 ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS Technische Universität Berlin (DE) 2023-11-02 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-08-22 US disclosed
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-08-22 US disclosed
US-20230242534-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-03 US disclosed
US-20230242534-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-03 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20110064698-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20110064698-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-10-21 US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 US disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20080027036-A1 S1P receptor modulating compounds and use thereof EPIX DELAWARE, INC. (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027036-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 HSD17B10 3082/4885KDM4E 1855/4885LMNA 3581/4885
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885
US-20100267634-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 HSD17B10 853/4885KDM4E 4556/4885LMNA 1121/4885
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof ACP1, PTPRCAP, PTPRO HSD17B10 2219/4885KDM4E 1140/4885LMNA 3754/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA HSD17B10 1268/4885KDM4E 4219/4885LMNA 2015/4885
US-20230242534-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF CDK2, CDK5, CDK9 HSD17B10 3107/4885KDM4E 1465/4885LMNA 1562/4885
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 HSD17B10 1114/4885KDM4E 1349/4885LMNA 3002/4885
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 HSD17B10 1019/4885KDM4E 537/4885LMNA 3035/4885
US-20230348422-A1 ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS ALB, AAAS, INF2 HSD17B10 1919/4885KDM4E 4857/4885LMNA 3594/4885
US-20110064698-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 HSD17B10 3314/4885KDM4E 2496/4885LMNA 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.